PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy Article Swipe
Yuka Suzuki
,
Kei Kohno
,
Kosei Matsue
,
Ayako Sakakibara
,
Eri Ishikawa
,
Satoko Shimada
,
Kazuyuki Shimada
,
Seiyo Mabuchi
,
Taishi Takahara
,
Seiichi Kato
,
Shigeo Nakamura
,
Akira Satou
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1002/cam4.3104
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1002/cam4.3104
Background Intravascular large B‐cell lymphoma (IVLBCL) is a rare form of diffuse large B‐cell lymphoma (DLBCL) arising in extranodal sites. PD‐L1 expression of tumor cells has been reported in IVLBCL cells, but its clinicopathological relevance remains to be elucidated. Aims This study was aimed to reveal the characteristics of PD‐L1 + IVLBCL. Methods and results Neoplastic PD‐L1 expression was examined in 34 cases of IVLBCL and clinicopathological characteristics between patients with PD‐L1 + and PD‐L1 − IVLBCL were compared. We assessed PD‐L1 expression with SP142 antibody. Twelve (35%) of 34 cases showed positivity for PD‐L1. The PD‐L1 + group had significantly lower survival rates compared to the PD‐L1 − group. The PD‐L1 + IVLBCL group also had a significantly lower age distribution and a lower frequency of patients older than 60 years compared to the PD‐L1 − group. Very recently, we speculate that there is possible link between PD‐L1 + IVLBCL and PD‐L1 + extranodal DLBCL‐NOS (eDLBCL) because features of the two groups showed overlapping. Therefore, we compared the clinicopathological characteristics of the PD‐L1 + IVLBCL and PD‐L1 + eDLBCL. There were no significant differences in clinicopathological parameters and prognosis. Conclusion The worse prognosis of the PD‐L1 + group might be caused by immune evasion mechanisms, which are linked to PD‐L1 expression. Therefore, PD‐L1 + IVLBCL cases might be regarded as good candidates for targeted immunotherapy. We also highlighted the overlapping features of PD‐L1 + IVLBCL and PD‐L1 + eDLBCL. This result suggests that they should be regarded as one entity, immune evasion‐related extranodal large B‐cell lymphoma.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1002/cam4.3104
- https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3104
- OA Status
- gold
- Cited By
- 19
- References
- 51
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3023407502
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3023407502Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1002/cam4.3104Digital Object Identifier
- Title
-
PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-05-05Full publication date if available
- Authors
-
Yuka Suzuki, Kei Kohno, Kosei Matsue, Ayako Sakakibara, Eri Ishikawa, Satoko Shimada, Kazuyuki Shimada, Seiyo Mabuchi, Taishi Takahara, Seiichi Kato, Shigeo Nakamura, Akira SatouList of authors in order
- Landing page
-
https://doi.org/10.1002/cam4.3104Publisher landing page
- PDF URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3104Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3104Direct OA link when available
- Concepts
-
Intravascular large B-cell lymphoma, Lymphoma, Immunohistochemistry, Medicine, PD-L1, Rituximab, Chemotherapy, Immune system, Immunotherapy, Pathology, Internal medicine, Cancer research, ImmunologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
19Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3, 2024: 2, 2023: 2, 2022: 3, 2021: 6Per-year citation counts (last 5 years)
- References (count)
-
51Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3023407502 |
|---|---|
| doi | https://doi.org/10.1002/cam4.3104 |
| ids.doi | https://doi.org/10.1002/cam4.3104 |
| ids.mag | 3023407502 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/32367674 |
| ids.openalex | https://openalex.org/W3023407502 |
| fwci | 1.57378418 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000367 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Age Factors |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000368 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Aged |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D000369 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Aged, 80 and over |
| mesh[3].qualifier_ui | Q000627 |
| mesh[3].descriptor_ui | D000971 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | therapeutic use |
| mesh[3].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[4].qualifier_ui | Q000378 |
| mesh[4].descriptor_ui | D060890 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | metabolism |
| mesh[4].descriptor_name | B7-H1 Antigen |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D005260 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Female |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D006801 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Humans |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D057131 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Immune Evasion |
| mesh[8].qualifier_ui | Q000188 |
| mesh[8].descriptor_ui | D016403 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | drug therapy |
| mesh[8].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[9].qualifier_ui | Q000378 |
| mesh[9].descriptor_ui | D016403 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | metabolism |
| mesh[9].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[10].qualifier_ui | Q000401 |
| mesh[10].descriptor_ui | D016403 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | mortality |
| mesh[10].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[11].qualifier_ui | Q000473 |
| mesh[11].descriptor_ui | D016403 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | pathology |
| mesh[11].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D008297 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Male |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D008875 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Middle Aged |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D011379 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Prognosis |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D012189 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Retrospective Studies |
| mesh[16].qualifier_ui | Q000627 |
| mesh[16].descriptor_ui | D000069283 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | therapeutic use |
| mesh[16].descriptor_name | Rituximab |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D015996 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Survival Rate |
| mesh[18].qualifier_ui | Q000276 |
| mesh[18].descriptor_ui | D019139 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | immunology |
| mesh[18].descriptor_name | Tumor Escape |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D000367 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Age Factors |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D000368 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Aged |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D000369 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Aged, 80 and over |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D000971 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[23].qualifier_ui | Q000378 |
| mesh[23].descriptor_ui | D060890 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | metabolism |
| mesh[23].descriptor_name | B7-H1 Antigen |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D005260 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Female |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D006801 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Humans |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D057131 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Immune Evasion |
| mesh[27].qualifier_ui | Q000188 |
| mesh[27].descriptor_ui | D016403 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | drug therapy |
| mesh[27].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[28].qualifier_ui | Q000378 |
| mesh[28].descriptor_ui | D016403 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | metabolism |
| mesh[28].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[29].qualifier_ui | Q000401 |
| mesh[29].descriptor_ui | D016403 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | mortality |
| mesh[29].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[30].qualifier_ui | Q000473 |
| mesh[30].descriptor_ui | D016403 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | pathology |
| mesh[30].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D008297 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Male |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D008875 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Middle Aged |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D011379 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Prognosis |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D012189 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Retrospective Studies |
| mesh[35].qualifier_ui | Q000627 |
| mesh[35].descriptor_ui | D000069283 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | therapeutic use |
| mesh[35].descriptor_name | Rituximab |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D015996 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Survival Rate |
| mesh[37].qualifier_ui | Q000276 |
| mesh[37].descriptor_ui | D019139 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | immunology |
| mesh[37].descriptor_name | Tumor Escape |
| type | article |
| title | PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy |
| biblio.issue | 13 |
| biblio.volume | 9 |
| biblio.last_page | 4776 |
| biblio.first_page | 4768 |
| topics[0].id | https://openalex.org/T12212 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2728 |
| topics[0].subfield.display_name | Neurology |
| topics[0].display_name | CNS Lymphoma Diagnosis and Treatment |
| topics[1].id | https://openalex.org/T10185 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9987999796867371 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2734 |
| topics[1].subfield.display_name | Pathology and Forensic Medicine |
| topics[1].display_name | Lymphoma Diagnosis and Treatment |
| topics[2].id | https://openalex.org/T10129 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9918000102043152 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2716 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Glioma Diagnosis and Treatment |
| is_xpac | False |
| apc_list.value | 2300 |
| apc_list.currency | EUR |
| apc_list.value_usd | 3025 |
| apc_paid.value | 2300 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 3025 |
| concepts[0].id | https://openalex.org/C2780151071 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8903161287307739 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q6058570 |
| concepts[0].display_name | Intravascular large B-cell lymphoma |
| concepts[1].id | https://openalex.org/C2779338263 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6454019546508789 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[1].display_name | Lymphoma |
| concepts[2].id | https://openalex.org/C204232928 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6018915772438049 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q899285 |
| concepts[2].display_name | Immunohistochemistry |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.5585193634033203 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C2781053074 |
| concepts[4].level | 4 |
| concepts[4].score | 0.5364708304405212 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q21100639 |
| concepts[4].display_name | PD-L1 |
| concepts[5].id | https://openalex.org/C2780653079 |
| concepts[5].level | 3 |
| concepts[5].score | 0.49707654118537903 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q412323 |
| concepts[5].display_name | Rituximab |
| concepts[6].id | https://openalex.org/C2776694085 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4371567368507385 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[6].display_name | Chemotherapy |
| concepts[7].id | https://openalex.org/C8891405 |
| concepts[7].level | 2 |
| concepts[7].score | 0.43518057465553284 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[7].display_name | Immune system |
| concepts[8].id | https://openalex.org/C2777701055 |
| concepts[8].level | 3 |
| concepts[8].score | 0.4236561954021454 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[8].display_name | Immunotherapy |
| concepts[9].id | https://openalex.org/C142724271 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3834090530872345 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[9].display_name | Pathology |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.37274599075317383 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| concepts[11].id | https://openalex.org/C502942594 |
| concepts[11].level | 1 |
| concepts[11].score | 0.33676356077194214 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[11].display_name | Cancer research |
| concepts[12].id | https://openalex.org/C203014093 |
| concepts[12].level | 1 |
| concepts[12].score | 0.24290281534194946 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[12].display_name | Immunology |
| keywords[0].id | https://openalex.org/keywords/intravascular-large-b-cell-lymphoma |
| keywords[0].score | 0.8903161287307739 |
| keywords[0].display_name | Intravascular large B-cell lymphoma |
| keywords[1].id | https://openalex.org/keywords/lymphoma |
| keywords[1].score | 0.6454019546508789 |
| keywords[1].display_name | Lymphoma |
| keywords[2].id | https://openalex.org/keywords/immunohistochemistry |
| keywords[2].score | 0.6018915772438049 |
| keywords[2].display_name | Immunohistochemistry |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.5585193634033203 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/pd-l1 |
| keywords[4].score | 0.5364708304405212 |
| keywords[4].display_name | PD-L1 |
| keywords[5].id | https://openalex.org/keywords/rituximab |
| keywords[5].score | 0.49707654118537903 |
| keywords[5].display_name | Rituximab |
| keywords[6].id | https://openalex.org/keywords/chemotherapy |
| keywords[6].score | 0.4371567368507385 |
| keywords[6].display_name | Chemotherapy |
| keywords[7].id | https://openalex.org/keywords/immune-system |
| keywords[7].score | 0.43518057465553284 |
| keywords[7].display_name | Immune system |
| keywords[8].id | https://openalex.org/keywords/immunotherapy |
| keywords[8].score | 0.4236561954021454 |
| keywords[8].display_name | Immunotherapy |
| keywords[9].id | https://openalex.org/keywords/pathology |
| keywords[9].score | 0.3834090530872345 |
| keywords[9].display_name | Pathology |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.37274599075317383 |
| keywords[10].display_name | Internal medicine |
| keywords[11].id | https://openalex.org/keywords/cancer-research |
| keywords[11].score | 0.33676356077194214 |
| keywords[11].display_name | Cancer research |
| keywords[12].id | https://openalex.org/keywords/immunology |
| keywords[12].score | 0.24290281534194946 |
| keywords[12].display_name | Immunology |
| language | en |
| locations[0].id | doi:10.1002/cam4.3104 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2754843627 |
| locations[0].source.issn | 2045-7634 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2045-7634 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Cancer Medicine |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3104 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cancer Medicine |
| locations[0].landing_page_url | https://doi.org/10.1002/cam4.3104 |
| locations[1].id | pmid:32367674 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cancer medicine |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/32367674 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:7333862 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Cancer Med |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7333862 |
| locations[3].id | pmh:oai:doaj.org/article:4c0f6a28f0514d4da1caa99d2011effe |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | cc-by-sa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Cancer Medicine, Vol 9, Iss 13, Pp 4768-4776 (2020) |
| locations[3].landing_page_url | https://doaj.org/article/4c0f6a28f0514d4da1caa99d2011effe |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5056944762 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2288-7162 |
| authorships[0].author.display_name | Yuka Suzuki |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210090647 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I4210090647 |
| authorships[0].institutions[0].ror | https://ror.org/008zz8m46 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210090647 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Nagoya University Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Yuka Suzuki |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[1].author.id | https://openalex.org/A5029594974 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-3738-5461 |
| authorships[1].author.display_name | Kei Kohno |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210090647 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I4210090647 |
| authorships[1].institutions[0].ror | https://ror.org/008zz8m46 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210090647 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Nagoya University Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Kei Kohno |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[2].author.id | https://openalex.org/A5025340212 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-8669-9865 |
| authorships[2].author.display_name | Kosei Matsue |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210114023 |
| authorships[2].affiliations[0].raw_affiliation_string | Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Centre, Kamogawa, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I4210114023 |
| authorships[2].institutions[0].ror | https://ror.org/01gf00k84 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210114023 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Kameda Medical Center |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Kosei Matsue |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Centre, Kamogawa, Japan |
| authorships[3].author.id | https://openalex.org/A5033702969 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-2117-1266 |
| authorships[3].author.display_name | Ayako Sakakibara |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210090647 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I4210090647 |
| authorships[3].institutions[0].ror | https://ror.org/008zz8m46 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210090647 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Nagoya University Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Ayako Sakakibara |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[4].author.id | https://openalex.org/A5071636090 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-1623-7996 |
| authorships[4].author.display_name | Eri Ishikawa |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210090647 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[4].affiliations[1].institution_ids | https://openalex.org/I60134161 |
| authorships[4].affiliations[1].raw_affiliation_string | Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I60134161 |
| authorships[4].institutions[0].ror | https://ror.org/04chrp450 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I60134161 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Nagoya University |
| authorships[4].institutions[1].id | https://openalex.org/I4210090647 |
| authorships[4].institutions[1].ror | https://ror.org/008zz8m46 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I4210090647 |
| authorships[4].institutions[1].country_code | JP |
| authorships[4].institutions[1].display_name | Nagoya University Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Eri Ishikawa |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[5].author.id | https://openalex.org/A5058578824 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Satoko Shimada |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210090647 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I4210090647 |
| authorships[5].institutions[0].ror | https://ror.org/008zz8m46 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210090647 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Nagoya University Hospital |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Satoko Shimada |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[6].author.id | https://openalex.org/A5068557516 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-1075-9219 |
| authorships[6].author.display_name | Kazuyuki Shimada |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I60134161 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Haematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I60134161 |
| authorships[6].institutions[0].ror | https://ror.org/04chrp450 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I60134161 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Nagoya University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Kazuyuki Shimada |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Haematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan |
| authorships[7].author.id | https://openalex.org/A5108284716 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Seiyo Mabuchi |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210090647 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I4210090647 |
| authorships[7].institutions[0].ror | https://ror.org/008zz8m46 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210090647 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Nagoya University Hospital |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Seiyo Mabuchi |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[8].author.id | https://openalex.org/A5056557726 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-9219-8357 |
| authorships[8].author.display_name | Taishi Takahara |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210099598 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I4210099598 |
| authorships[8].institutions[0].ror | https://ror.org/00ztar512 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I16528096, https://openalex.org/I4210099598 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Aichi Medical University Hospital |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Taishi Takahara |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan |
| authorships[9].author.id | https://openalex.org/A5003492342 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-9713-3691 |
| authorships[9].author.display_name | Seiichi Kato |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210133851 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Pathology and Molecular Diagnostics, Aichi Cancer Centre Hospital, Nagoya, Japan |
| authorships[9].institutions[0].id | https://openalex.org/I4210133851 |
| authorships[9].institutions[0].ror | https://ror.org/03kfmm080 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210133851 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Aichi Cancer Center |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Seiichi Kato |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Pathology and Molecular Diagnostics, Aichi Cancer Centre Hospital, Nagoya, Japan |
| authorships[10].author.id | https://openalex.org/A5113553546 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Shigeo Nakamura |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210090647 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[10].institutions[0].id | https://openalex.org/I4210090647 |
| authorships[10].institutions[0].ror | https://ror.org/008zz8m46 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210090647 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | Nagoya University Hospital |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Shigeo Nakamura |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan |
| authorships[11].author.id | https://openalex.org/A5059183289 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-7921-6087 |
| authorships[11].author.display_name | Akira Satou |
| authorships[11].countries | JP |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210099598 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan |
| authorships[11].institutions[0].id | https://openalex.org/I4210099598 |
| authorships[11].institutions[0].ror | https://ror.org/00ztar512 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I16528096, https://openalex.org/I4210099598 |
| authorships[11].institutions[0].country_code | JP |
| authorships[11].institutions[0].display_name | Aichi Medical University Hospital |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | Akira Satou |
| authorships[11].is_corresponding | True |
| authorships[11].raw_affiliation_strings | Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3104 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | PD‐L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B‐cell lymphoma treated with rituximab‐based multi‐agent chemotherapy |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12212 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2728 |
| primary_topic.subfield.display_name | Neurology |
| primary_topic.display_name | CNS Lymphoma Diagnosis and Treatment |
| related_works | https://openalex.org/W2411583971, https://openalex.org/W2781286807, https://openalex.org/W89545156, https://openalex.org/W2135979319, https://openalex.org/W1903196532, https://openalex.org/W2121565863, https://openalex.org/W3157549915, https://openalex.org/W4388856884, https://openalex.org/W2089297256, https://openalex.org/W2005003390 |
| cited_by_count | 19 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 2 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 3 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 6 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 3 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1002/cam4.3104 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2754843627 |
| best_oa_location.source.issn | 2045-7634 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2045-7634 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Cancer Medicine |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3104 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cancer Medicine |
| best_oa_location.landing_page_url | https://doi.org/10.1002/cam4.3104 |
| primary_location.id | doi:10.1002/cam4.3104 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2754843627 |
| primary_location.source.issn | 2045-7634 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2045-7634 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Cancer Medicine |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.3104 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cancer Medicine |
| primary_location.landing_page_url | https://doi.org/10.1002/cam4.3104 |
| publication_date | 2020-05-05 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W2885385993, https://openalex.org/W1988957481, https://openalex.org/W2054098911, https://openalex.org/W2907509816, https://openalex.org/W2793309682, https://openalex.org/W2108155321, https://openalex.org/W1969982030, https://openalex.org/W2155464214, https://openalex.org/W2608950674, https://openalex.org/W2125616358, https://openalex.org/W2412725897, https://openalex.org/W2586276931, https://openalex.org/W2925446385, https://openalex.org/W2600581432, https://openalex.org/W1241485355, https://openalex.org/W1135493307, https://openalex.org/W2463010577, https://openalex.org/W1815157104, https://openalex.org/W2140010961, https://openalex.org/W2029086221, https://openalex.org/W2794201914, https://openalex.org/W2337659275, https://openalex.org/W2786224778, https://openalex.org/W2930809663, https://openalex.org/W2907903370, https://openalex.org/W2911357875, https://openalex.org/W2972238069, https://openalex.org/W2158267770, https://openalex.org/W2147240268, https://openalex.org/W2321985702, https://openalex.org/W2792417314, https://openalex.org/W2805861266, https://openalex.org/W2900885205, https://openalex.org/W2910080320, https://openalex.org/W2936293163, https://openalex.org/W2790762918, https://openalex.org/W94592798, https://openalex.org/W1745886051, https://openalex.org/W2030841669, https://openalex.org/W2115091768, https://openalex.org/W1986354050, https://openalex.org/W2529923789, https://openalex.org/W2597459296, https://openalex.org/W2622400061, https://openalex.org/W2116382435, https://openalex.org/W2095737226, https://openalex.org/W1510576016, https://openalex.org/W1981152938, https://openalex.org/W1482778630, https://openalex.org/W2790348403, https://openalex.org/W1605230984 |
| referenced_works_count | 51 |
| abstract_inverted_index.+ | 51, 73, 98, 113, 150, 154, 175, 179, 198, 215, 235, 239 |
| abstract_inverted_index.a | 8, 118, 124 |
| abstract_inverted_index.34 | 62, 90 |
| abstract_inverted_index.60 | 131 |
| abstract_inverted_index.We | 80, 227 |
| abstract_inverted_index.as | 221, 249 |
| abstract_inverted_index.be | 38, 201, 219, 247 |
| abstract_inverted_index.by | 203 |
| abstract_inverted_index.in | 18, 29, 61, 186 |
| abstract_inverted_index.is | 7, 145 |
| abstract_inverted_index.no | 183 |
| abstract_inverted_index.of | 11, 23, 49, 64, 89, 127, 160, 172, 195, 233 |
| abstract_inverted_index.to | 37, 45, 106, 134, 210 |
| abstract_inverted_index.we | 141, 167 |
| abstract_inverted_index.The | 96, 111, 192 |
| abstract_inverted_index.age | 121 |
| abstract_inverted_index.and | 54, 66, 74, 123, 152, 177, 189, 237 |
| abstract_inverted_index.are | 208 |
| abstract_inverted_index.but | 32 |
| abstract_inverted_index.for | 94, 224 |
| abstract_inverted_index.had | 100, 117 |
| abstract_inverted_index.has | 26 |
| abstract_inverted_index.its | 33 |
| abstract_inverted_index.one | 250 |
| abstract_inverted_index.the | 47, 107, 135, 161, 169, 173, 196, 230 |
| abstract_inverted_index.two | 162 |
| abstract_inverted_index.was | 43, 59 |
| abstract_inverted_index.− | 76, 109, 137 |
| abstract_inverted_index.Aims | 40 |
| abstract_inverted_index.This | 41, 241 |
| abstract_inverted_index.Very | 139 |
| abstract_inverted_index.also | 116, 228 |
| abstract_inverted_index.been | 27 |
| abstract_inverted_index.form | 10 |
| abstract_inverted_index.good | 222 |
| abstract_inverted_index.link | 147 |
| abstract_inverted_index.rare | 9 |
| abstract_inverted_index.than | 130 |
| abstract_inverted_index.that | 143, 244 |
| abstract_inverted_index.they | 245 |
| abstract_inverted_index.were | 78, 182 |
| abstract_inverted_index.with | 71, 84 |
| abstract_inverted_index.(35%) | 88 |
| abstract_inverted_index.SP142 | 85 |
| abstract_inverted_index.There | 181 |
| abstract_inverted_index.aimed | 44 |
| abstract_inverted_index.cases | 63, 91, 217 |
| abstract_inverted_index.cells | 25 |
| abstract_inverted_index.group | 99, 115, 199 |
| abstract_inverted_index.large | 3, 13, 255 |
| abstract_inverted_index.lower | 102, 120, 125 |
| abstract_inverted_index.might | 200, 218 |
| abstract_inverted_index.older | 129 |
| abstract_inverted_index.rates | 104 |
| abstract_inverted_index.study | 42 |
| abstract_inverted_index.there | 144 |
| abstract_inverted_index.tumor | 24 |
| abstract_inverted_index.which | 207 |
| abstract_inverted_index.worse | 193 |
| abstract_inverted_index.years | 132 |
| abstract_inverted_index.IVLBCL | 30, 65, 77, 114, 151, 176, 216, 236 |
| abstract_inverted_index.Twelve | 87 |
| abstract_inverted_index.caused | 202 |
| abstract_inverted_index.cells, | 31 |
| abstract_inverted_index.group. | 110, 138 |
| abstract_inverted_index.groups | 163 |
| abstract_inverted_index.immune | 204, 252 |
| abstract_inverted_index.linked | 209 |
| abstract_inverted_index.result | 242 |
| abstract_inverted_index.reveal | 46 |
| abstract_inverted_index.should | 246 |
| abstract_inverted_index.showed | 92, 164 |
| abstract_inverted_index.sites. | 20 |
| abstract_inverted_index.(DLBCL) | 16 |
| abstract_inverted_index.IVLBCL. | 52 |
| abstract_inverted_index.Methods | 53 |
| abstract_inverted_index.PD‐L1 | 21, 50, 57, 72, 75, 82, 97, 108, 112, 136, 149, 153, 174, 178, 197, 211, 214, 234, 238 |
| abstract_inverted_index.arising | 17 |
| abstract_inverted_index.because | 158 |
| abstract_inverted_index.between | 69, 148 |
| abstract_inverted_index.diffuse | 12 |
| abstract_inverted_index.eDLBCL. | 180, 240 |
| abstract_inverted_index.entity, | 251 |
| abstract_inverted_index.evasion | 205 |
| abstract_inverted_index.remains | 36 |
| abstract_inverted_index.results | 55 |
| abstract_inverted_index.(IVLBCL) | 6 |
| abstract_inverted_index.(eDLBCL) | 157 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.B‐cell | 4, 14, 256 |
| abstract_inverted_index.PD‐L1. | 95 |
| abstract_inverted_index.assessed | 81 |
| abstract_inverted_index.compared | 105, 133, 168 |
| abstract_inverted_index.examined | 60 |
| abstract_inverted_index.features | 159, 232 |
| abstract_inverted_index.lymphoma | 5, 15 |
| abstract_inverted_index.patients | 70, 128 |
| abstract_inverted_index.possible | 146 |
| abstract_inverted_index.regarded | 220, 248 |
| abstract_inverted_index.reported | 28 |
| abstract_inverted_index.suggests | 243 |
| abstract_inverted_index.survival | 103 |
| abstract_inverted_index.targeted | 225 |
| abstract_inverted_index.antibody. | 86 |
| abstract_inverted_index.compared. | 79 |
| abstract_inverted_index.frequency | 126 |
| abstract_inverted_index.lymphoma. | 257 |
| abstract_inverted_index.prognosis | 194 |
| abstract_inverted_index.recently, | 140 |
| abstract_inverted_index.relevance | 35 |
| abstract_inverted_index.speculate | 142 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 191 |
| abstract_inverted_index.Neoplastic | 56 |
| abstract_inverted_index.Therefore, | 166, 213 |
| abstract_inverted_index.candidates | 223 |
| abstract_inverted_index.expression | 22, 58, 83 |
| abstract_inverted_index.extranodal | 19, 155, 254 |
| abstract_inverted_index.parameters | 188 |
| abstract_inverted_index.positivity | 93 |
| abstract_inverted_index.prognosis. | 190 |
| abstract_inverted_index.DLBCL‐NOS | 156 |
| abstract_inverted_index.differences | 185 |
| abstract_inverted_index.elucidated. | 39 |
| abstract_inverted_index.expression. | 212 |
| abstract_inverted_index.highlighted | 229 |
| abstract_inverted_index.mechanisms, | 206 |
| abstract_inverted_index.overlapping | 231 |
| abstract_inverted_index.significant | 184 |
| abstract_inverted_index.distribution | 122 |
| abstract_inverted_index.overlapping. | 165 |
| abstract_inverted_index.Intravascular | 2 |
| abstract_inverted_index.significantly | 101, 119 |
| abstract_inverted_index.immunotherapy. | 226 |
| abstract_inverted_index.characteristics | 48, 68, 171 |
| abstract_inverted_index.evasion‐related | 253 |
| abstract_inverted_index.clinicopathological | 34, 67, 170, 187 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5059183289 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 12 |
| corresponding_institution_ids | https://openalex.org/I4210099598 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/1 |
| sustainable_development_goals[0].score | 0.5299999713897705 |
| sustainable_development_goals[0].display_name | No poverty |
| citation_normalized_percentile.value | 0.83512458 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |